Steering committee


The TARGIT International Steering Committee and Data Monitoring Committee


Prof Michael Baum 

Professor Emeritus of Surgery, and Director of the Clinilcal Trials Group, Division of Surgery and Interventional Science, University College London, UK. He has pioneered several new treatments for breast cancer including tamoxifen and anastrazole. He conceived the TARGIT trial along with Jayant Vaidya and Professor Jeffrey Tobias.  He has been awarded several prestigious awards including the St Gallen Prize for lifetime achievement.





Prof David Joseph

Clinical Professor,
Department of Radiation Oncology,
Sir Charles Gairdner Hospital,
Western Australia




Members of the Steering committee


Jayant S Vaidya, Research Department of Surgery, Division of Surgery and Interventional Science, University College London, UK, is the co-inventor of the TARGIT technique, conceived and designed  the TARGIT trial along with Professor Michael Baum and Professor Jeffrey Tobias.  He coined the word TARGIT for TARGeted Intraoperative radioTherapy. He was instrumental in setting up the TARGIT-A and TARGIT-B trials in several centres. He is particularly interested in translational research and novel effect of radiotherapy on tumour microenvironment



Jeffrey S TobiasDepartment of Clinical Oncology, University College London Hospitals, London, UK.

Professor Tobias designed the TARGIT trial along with along with Jayant Vaidya and Professor Michael Baum and has been involved with the TARGIT approach from the very beginning. His other interests are Head and Neck cancer and Lung cancer.



 Frederik WenzDepartment of Radiation Oncology, University Medical Centre Mannheim, University of Heidelberg, Germany 

He is particularly interested in the interesting radiobiology of the TARGIT technique and has published widely on the toxicity data of TARGIT- both acute and late and has developed new radiobiological models and concepts on dosimetry such as  'sphere of equivalence'. His other interests are in prostate cancer and bony metastasis.  






Christobel Saunders, School of Surgery, University of Western Australia, Perth, WA, Australia.

She was involved with the TARGIT trial at UCL and then at Perth. 






Mohammed Keshtgar, Department of Surgery, Royal Free Hospital and University College London Medical School, London, UK

He has published on use of TARGIT technique in special circumstances. His main area of research interest is minimally invasive approaches in breast cancer management.   





Laura Esserman, Department of Surgery, University of California, San Francisco, CA, USA

 Dr. Esserman led the effort to get the University of California, San Francisco as the first U.S. site to participate in the trial






Tammy Corica, Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia

Max Bulsara, Department of Biostatistics, University of Notre Dame, Freemantle, Australia

He is a co-investigator and collaborator on many research grants with leading researchers in Australia and overseas. He has been involved in Epidemiological research for over two decades and has published widely. He teaches and supervises higher degree students. He has been involved with the statistical aspects of the TARGIT trial.






 Uta Kraus-Tiefenbacher, Department of Radiation Oncology, University Medical Centre Mannheim, University of Heidelberg, Germany

Wolfgang Eiermann, Department of Surgery, University of Munich, Munich, Germany








Norman R Williams, Clinical Trials Group, Division of Surgery and Interventional Science University College London, London, UK

Samuele Massarut, Department of Surgery, Centro di Riferimento Oncologia, Aviano, Italy 








John Dewar, Department of Radiation Oncology, Ninewells Hospital, Dundee, UK

Marinos Metaxas, Department of Radiation Physics, University College London Hospitals, London, UK  

Marc Sütterlin, Department of Gynecology and Obstetrics (M Sütterlin), University Medical Centre Mannheim, University of Heidelberg, Germany 

Michael Alvarado, Department of Surgery, University of California, San Francisco, CA, USA








Henrik Flyger, Head, Department of Breast Surgery, University of Copenhagen, Copenhagen, Denmark 







Mary Falzon, Department of Pathology, University College London Hospitals, London, UK

Dr Mary Falzon is a consultant/Hon Sen Lecturer in pathology at University college Hospital, London. Her specialist areas are Breast and Lung pathology and cytopathology.





April Matthews, Lay member and keenly interested in breast cancer trials

 April is a Social Scientist and since 2001 has worked as a Patient Advocate with teams researching on clinical trial studies based at Universities in London, Leeds, Manchester and Liverpool.